Cannara Biotech Inc. (LOVFF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannara Biotech Inc. (LOVFF) trades at $1.30 with AI Score 49/100 (Grade C). Cannara Biotech Inc. cultivates, processes, and sells cannabis and cannabis-derived products in Canada. Market cap: $128.42M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for LOVFF: LOVFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LOVFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LOVFF: the 1 perspectives are evenly split.
How is this calculated? →Cannara Biotech Inc. (LOVFF) Healthcare & Pipeline Overview
Cannara Biotech Inc. is a Canadian cannabis company focused on indoor cultivation, processing, and sale of cannabis and cannabis-derived products. Operating in the specialty and generic drug manufacturing sector, the company also distributes hemp-based CBD products through its e-commerce platform, holding a niche position in the Canadian market.
What Is the Investment Thesis for LOVFF?
Cannara Biotech Inc. presents a focused investment opportunity within the Canadian cannabis market. With a market capitalization of $128.42M and a P/E ratio of 12.9, the company demonstrates potential for growth and profitability. A gross margin of 38.6% and a profit margin of 10.5% indicate efficient operations. Catalysts include expansion of its product line and increased market penetration within Canada. However, investors may want to evaluate the risks associated with regulatory changes in the cannabis industry and competition from larger players. The company's beta of 0.34 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
LOVFF Key Highlights
- Market Cap of $128.42M indicates the company's current valuation in the market.
- P/E ratio of 12.9 suggests the stock may be undervalued compared to its earnings.
- Gross Margin of 38.6% reflects the efficiency of the company's production process.
- Profit Margin of 10.5% demonstrates the company's ability to generate profit after all expenses.
- Beta of 0.34 indicates lower volatility compared to the overall market.
Who Are LOVFF's Competitors?
LOVFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOYF BioSyent Inc. | $10.31 | +1.28% | $117.93M | 50 |
| CBWTF Auxly Cannabis Group Inc. | $0.13 | +2.50% | $179.62M | 54 |
| GRUSF Grown Rogue International Inc. | $0.47 | +2.35% | $117.67M | 43 |
| HLTRF HLS Therapeutics Inc. | $3.00 | +0.00% | $93.82M | 48 |
| KNTPF Kintor Pharmaceutical Limited | $0.25 | +0.00% | $115.49M | 56 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LOVFF's Key Strengths?
- Indoor cultivation provides control over product quality.
- Established presence in the Canadian cannabis market.
- E-commerce platform for CBD product sales.
- Experienced management team.
What Are LOVFF's Weaknesses?
- Limited geographic diversification.
- Reliance on the Canadian cannabis market.
- Smaller scale compared to larger competitors.
- OTC listing may limit investor access.
What Could Drive LOVFF Stock Higher?
- Potential regulatory changes in the Canadian cannabis market could create new opportunities or challenges for Cannara Biotech.
- Expansion of the company's product line to include new cannabis products.
- Increased market penetration in Canada through expanded distribution networks.
- Growth of the e-commerce platform for CBD products.
- Strategic partnerships and acquisitions to expand capabilities and market reach.
What Are the Key Risks for LOVFF?
- Evolving cannabis regulations could negatively impact the company's operations and profitability.
- Intense competition from other cannabis companies could erode market share.
- Fluctuations in cannabis prices could affect revenue and profitability.
- Changes in consumer preferences could impact demand for the company's products.
- The company's OTC listing may limit investor access and liquidity.
What Are the Growth Opportunities for LOVFF?
- Expansion of Product Line: Cannara Biotech has the opportunity to expand its product line to include new and innovative cannabis products. By introducing new strains, edibles, and concentrates, the company can attract a wider range of customers and increase its market share. The market for cannabis-infused products is projected to reach $2.5 billion by 2028, providing a significant growth opportunity for Cannara Biotech. Successful product innovation and marketing will be crucial for capturing this market share.
- Increased Market Penetration in Canada: Cannara Biotech can focus on increasing its market penetration within Canada. By expanding its distribution network and retail partnerships, the company can reach more customers and increase its sales volume. The Canadian cannabis market is still relatively young, with significant potential for growth. Cannara Biotech can capitalize on this opportunity by strengthening its brand presence and customer loyalty. Timeline for expansion is estimated at 2-3 years.
- E-commerce Platform Growth: Cannara Biotech can further develop its e-commerce platform to enhance online sales of hemp-based CBD products. The global CBD market is experiencing rapid growth, driven by increasing consumer awareness of the potential health benefits of CBD. By optimizing its e-commerce platform and implementing effective digital marketing strategies, Cannara Biotech can capture a larger share of the online CBD market. The global CBD market is projected to reach $47.22 billion by 2028.
- Strategic Partnerships and Acquisitions: Cannara Biotech can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By partnering with other cannabis companies, the company can gain access to new technologies, distribution networks, and customer bases. Acquisitions can provide Cannara Biotech with new product lines and market segments. Identifying and executing strategic partnerships and acquisitions will be crucial for accelerating the company's growth and competitiveness. This is an ongoing opportunity with no fixed timeline.
- International Expansion: Cannara Biotech can explore opportunities for international expansion, particularly in countries with favorable cannabis regulations. By entering new markets, the company can diversify its revenue streams and reduce its reliance on the Canadian market. International expansion requires careful planning and execution, including navigating regulatory requirements and cultural differences. However, the potential rewards are significant, as the global cannabis market is projected to reach $90.4 billion by 2026.
What Opportunities Does LOVFF Have?
- Expansion of product line to include new cannabis products.
- Increased market penetration in Canada.
- Growth of the e-commerce platform for CBD products.
- Strategic partnerships and acquisitions.
What Threats Does LOVFF Face?
- Evolving cannabis regulations.
- Intense competition from other cannabis companies.
- Fluctuations in cannabis prices.
- Potential changes in consumer preferences.
What Are LOVFF's Competitive Advantages?
- Focus on indoor cultivation allows for greater control over product quality and consistency.
- Established distribution network in the Canadian cannabis market.
- E-commerce platform provides direct access to consumers for CBD products.
What Does LOVFF Do?
Cannara Biotech Inc. was founded in 2017 and is headquartered in Saint-Laurent, Canada. The company operates in the cannabis industry, focusing on the cultivation, processing, and sale of cannabis and cannabis-derived products. Cannara Biotech utilizes indoor cultivation methods, allowing for greater control over the growing environment and product quality. The company's product portfolio includes a range of cannabis products, catering to both recreational and medicinal users in the Canadian market. In addition to cannabis products, Cannara Biotech also offers hemp-based CBD products through its e-commerce platform, expanding its reach to a broader consumer base. Cannara Biotech aims to establish itself as a leading player in the Canadian cannabis market through its focus on quality, innovation, and customer satisfaction. The company has 461 employees.
What Products and Services Does LOVFF Offer?
- Cultivates cannabis indoors to control growing conditions and product quality.
- Processes cannabis plants into various products, including dried flower, oils, and concentrates.
- Sells cannabis and cannabis-derived products to recreational and medicinal users in Canada.
- Offers hemp-based CBD products through its e-commerce platform.
- Focuses on product innovation to meet evolving consumer preferences.
- Distributes products through a network of retail partners and online channels.
How Does LOVFF Make Money?
- Generates revenue through the sale of cannabis and cannabis-derived products.
- Utilizes indoor cultivation to optimize product quality and yield.
- Distributes products through retail partnerships and an e-commerce platform.
What Industry Does LOVFF Operate In?
Cannara Biotech operates within the rapidly evolving Canadian cannabis industry. The market has experienced significant growth since legalization, driven by increasing consumer demand and product innovation. The industry is characterized by intense competition, with numerous players vying for market share. Cannara Biotech differentiates itself through its focus on indoor cultivation and a diverse product portfolio. The company must navigate evolving regulations and consumer preferences to maintain its competitive edge. The Canadian cannabis market is projected to continue growing, presenting opportunities for companies like Cannara Biotech to expand their operations and market presence.
Who Are LOVFF's Key Customers?
- Recreational cannabis users in Canada.
- Medicinal cannabis patients in Canada.
- Consumers interested in hemp-based CBD products.
ROE 9%Key Financial Metrics
Return on equity for Cannara Biotech Inc. stands at 9.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.6%, showing how much profit it generates from its asset base. LOVFF trades at a trailing price-to-earnings ratio of 12.86, below the Healthcare sector average of ~23x. Its free cash flow yield is 9.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.0%, the inverse of the P/E and a quick read on earnings relative to price.
How Cannara Biotech Inc. Is Valued
Cannara Biotech Inc. carries a market capitalization of $128.42M, placing it in the micro-cap category. Relative to its peer group, LOVFF's quantitative score of 49/100 is roughly in line with the peer average of 50/100.
F-Score 7/9Financial Health
Cannara Biotech Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.08 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Cannara Biotech Inc. revenue of about $119.5M for fiscal 2026, with EPS near $0.11. The estimate reflects 4 contributing analysts.
LOVFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Cannara's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with increased discussions surrounding Cannara's innovative product lines and market positioning.
- The company's strategic partnerships in the cannabis space are drawing attention, signaling potential for expanded distribution and revenue streams.
- Increased demand for cannabis products post-legalization in various regions is creating a favorable environment for Cannara's offerings.
Bear Case
- Concerns over regulatory challenges in the cannabis industry persist, which could impact Cannara's operational capabilities.
- Market competition is intensifying, with larger players potentially overshadowing Cannara's market share and growth prospects.
- Recent social media sentiment has shown some skepticism regarding Cannara's ability to scale effectively amidst industry volatility.
- Financial sustainability remains a question, as the company needs to demonstrate consistent revenue growth to alleviate investor concerns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
LOVFF Latest News
-
Pharmala Biotech Holdings And 2 Other TSX Penny Stocks To Consider
Yahoo! Finance: LOVFF News · May 20, 2026
LOVFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LOVFF.
Price Targets
Wall Street price target analysis for LOVFF.
LOVFF MoonshotScore
What does this score mean?
The MoonshotScore rates LOVFF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Zohar Krivorot
CEO
Zohar Krivorot is the CEO of Cannara Biotech Inc. His background includes experience in managing and scaling businesses. He has been involved in the cannabis industry for several years and brings a deep understanding of the market dynamics and regulatory landscape. His expertise lies in strategic planning, operational efficiency, and business development. He is responsible for leading Cannara Biotech's growth strategy and ensuring the company's long-term success.
Track Record: Under Zohar Krivorot's leadership, Cannara Biotech has focused on expanding its product line and increasing its market share in the Canadian cannabis market. He has overseen the development of the company's indoor cultivation facilities and the launch of its e-commerce platform for CBD products. His strategic decisions have contributed to the company's revenue growth and profitability. He continues to guide Cannara Biotech through the evolving cannabis industry landscape.
LOVFF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannara Biotech Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, as there is less regulatory oversight and information available to investors. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of fraud or mismanagement.
- Limited information availability makes it challenging to assess the company's financial health.
- Greater price volatility can lead to significant losses.
- OTC stocks may be subject to delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- The company has been in operation since 2017.
- The company has 461 employees.
- The company cultivates, processes, and sells cannabis products in Canada.
- The company has an e-commerce platform for CBD products.
Cannara Biotech Inc. Healthcare Stock: Key Questions Answered
What does Cannara Biotech Inc. do?
Cannara Biotech Inc. is a Canadian cannabis company that cultivates, processes, and sells cannabis and cannabis-derived products. The company operates indoor cultivation facilities to ensure product quality and consistency. It offers a range of cannabis products to recreational and medicinal users in Canada. Additionally, Cannara Biotech sells hemp-based CBD products through its e-commerce platform, expanding its reach to a broader consumer base. The company focuses on product innovation and distribution through retail partnerships and online channels.
What are the main risks for LOVFF?
Cannara Biotech faces several risks, including evolving cannabis regulations, intense competition, fluctuations in cannabis prices, and changes in consumer preferences. The Canadian cannabis market is subject to regulatory changes that could impact the company's operations and profitability. Competition from other cannabis companies could erode market share and pricing power. Fluctuations in cannabis prices could affect revenue and profitability. Changes in consumer preferences could impact demand for the company's products. Additionally, the company's OTC listing may limit investor access and liquidity.
What are the key factors to evaluate for LOVFF?
Cannara Biotech Inc. (LOVFF) holds an AI score of 49/100 (low). P/E: 12.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does LOVFF data refresh on this page?
LOVFF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LOVFF's recent stock price performance?
Cannara Biotech Inc. (LOVFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Indoor cultivation provides control over product quality. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LOVFF overvalued or undervalued right now?
Cannara Biotech Inc. (LOVFF) trades at 12.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LOVFF?
Before investing in Cannara Biotech Inc. (LOVFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LOVFF to a portfolio?
Key strength of Cannara Biotech Inc. (LOVFF): Indoor cultivation provides control over product quality. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.